| Literature DB >> 8899107 |
Abstract
Medical therapy of ulcerative colitis and Crohn's disease involves the control of active inflammation to obtain clinical remission and then maintaining that remission. Corticosteroids and 5-aminosalicylic acid are the mainstay of such management. Both have a wide range of properties and are able to inhibit many effector mechanisms which are potentially involved in mucosal inflammation. In in vitro assays, both are able to inhibit the release of a wide variety of pro-inflammatory and immunoregulatory cytokines. In vivo, such effects would limit tissue damage, prevent further amplification of the immune response and restore epithelial function.Entities:
Mesh:
Substances:
Year: 1996 PMID: 8899107 DOI: 10.1046/j.1365-2036.1996.22164026.x
Source DB: PubMed Journal: Aliment Pharmacol Ther ISSN: 0269-2813 Impact factor: 8.171